Black Diamond Therapeutics, Inc. (BDTX)
NASDAQ:BDTX
Want to see BDTX full AI Analyst Report?
BDTX Stock Chart & Stats
$3.06
-$0.07(-3.30%)
At close: 4:00 PM EST
$3.06
-$0.07(-3.30%)
Day’s Range― - ―
52-Week Range$1.75 - $4.94
Previous CloseN/A
Volume170.82K
Average Volume (3M)1.86M
Market Cap
$100.28M
Enterprise Value$115.02M
Total Cash (Recent Filing)$118.26M
Total Debt (Recent Filing)$17.88M
Price to Earnings (P/E)―
Beta2.35
Next Earnings
Aug 06, 2026EPS Estimate
-0.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.76
Shares Outstanding57,301,773
10 Day Avg. Volume1,300,010
30 Day Avg. Volume1,859,266
Financial Highlights & Ratios
PEG Ratio-0.05
Price to Book (P/B)1.23
Price to Sales (P/S)1.97
P/FCF Ratio4.67
Enterprise Value/Market Cap1.15
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-1.02K
Enterprise Value/Ebitda-3.02
Forecast
1Y Price Target
$10.25Price Target Upside234.97% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.65
Revenue Forecast (FY)$7.14M
Bulls Say, Bears Say
Bulls Say
Proprietary Discovery PlatformBDTX's mutation-targeting discovery platform focuses R&D on cancer-driving, genetically defined patient subsets. Over the medium term this specialization can improve target selection, increase trial efficiency, enable differentiated labeling in niche indications, and attract partnership interest.
Positive Phase 2 Silevertinib DataDurable Phase 2 results (PFS 15.2 months, high CNS response, maintained activity after dose reduction) materially strengthen the pivotal development path. This structural clinical proof increases the probability of regulatory success, partnering opportunities, and efficient pivotal design over the next several months.
Manageable LeverageRelatively low trailing debt and declining leverage provide financial flexibility uncommon in small biotechs. Manageable debt reduces near-term solvency and interest expense risks, making it easier to fund pivotal programs via partnerships or targeted financing without excessive strain on the balance sheet.
Bears Say
Renewed Cash BurnA return to substantial negative operating and free cash flow erodes runway and forces choices about program pacing. Over the medium term this increases the likelihood of dilutive financing or dependence on milestone-based partnerships, which can delay development timelines and dilute shareholders.
Volatile Revenue And EarningsExtreme year-to-year swings between one-off collaboration income and subsequent quarters with no revenue undermine predictability. This episodic income model complicates multi-year budgeting, heightens funding risk between deals, and reduces visibility into sustainable operational performance.
Small Scale And Limited Commercial CapacityWith only ~24 employees and no commercial product base, internal bandwidth to run multiple late-stage programs, scale manufacturing, or commercialize is limited. This increases execution risk, fosters reliance on CROs and partners, and may slow timeline momentum if rapid scale-up is required.
Black Diamond Therapeutics News
BDTX FAQ
What was Black Diamond Therapeutics, Inc.’s price range in the past 12 months?
Black Diamond Therapeutics, Inc. lowest stock price was $1.75 and its highest was $4.94 in the past 12 months.
What is Black Diamond Therapeutics, Inc.’s market cap?
Black Diamond Therapeutics, Inc.’s market cap is $100.28M.
When is Black Diamond Therapeutics, Inc.’s upcoming earnings report date?
Black Diamond Therapeutics, Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 52 days.
How were Black Diamond Therapeutics, Inc.’s earnings last quarter?
Black Diamond Therapeutics, Inc. released its earnings results on May 07, 2026. The company reported -$0.16 earnings per share for the quarter, beating the consensus estimate of -$0.184 by $0.024.
Is Black Diamond Therapeutics, Inc. overvalued?
According to Wall Street analysts Black Diamond Therapeutics, Inc.’s price is currently Undervalued.
Does Black Diamond Therapeutics, Inc. pay dividends?
Black Diamond Therapeutics, Inc. does not currently pay dividends.
What is Black Diamond Therapeutics, Inc.’s EPS estimate?
Black Diamond Therapeutics, Inc.’s EPS estimate is -0.2.
How many shares outstanding does Black Diamond Therapeutics, Inc. have?
Black Diamond Therapeutics, Inc. has 57,301,773 shares outstanding.
What happened to Black Diamond Therapeutics, Inc.’s price movement after its last earnings report?
Black Diamond Therapeutics, Inc. reported an EPS of -$0.16 in its last earnings report, beating expectations of -$0.184. Following the earnings report the stock price went down -3.546%.
Which hedge fund is a major shareholder of Black Diamond Therapeutics, Inc.?
Currently, no hedge funds are holding shares in BDTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Black Diamond Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$10.25 (234.97% Upside)
$10.25 (234.97% Upside)
Blogger Sentiment
Bullish
BDTX Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 101.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.6%
Last 30 Days ▲ 10.1%
Last 30 Days ▲ 10.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-27.98%
12-Months-Change
Fundamentals
Return on Equity
-36.37%
Trailing 12-Months
Asset Growth
-24.58%
Trailing 12-Months
Company Description
Black Diamond Therapeutics, Inc.
Black Diamond Therapeutics, Inc. is a biotechnology enterprise dedicated to discovering, advancing, and bringing to market therapeutic agents specifically designed for patients with genetically characterized tumors. A core part of its pipeline is BDTX-189, an irreversible small molecule inhibitor. This compound is engineered to neutralize oncogenic proteins driven by non-canonical epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) driver mutations. The firm is also progressing BDTX-1535, a brain-penetrant inhibitor addressing a range of EGFR mutations, including conventional, inherent resistance, and acquired resistance forms. Concurrently, it is advancing BDTX-4933, another brain-penetrant inhibitor targeting oncogenic BRAF alterations across Class I, II, and III categories. Black Diamond maintains a strategic alliance with OpenEye Scientific Software, Inc. Established in 2014, the company was initially known as ASET Therapeutics, Inc. before adopting its current name, Black Diamond Therapeutics, Inc., in January 2018. Its corporate headquarters are situated in Cambridge, Massachusetts.
BDTX Stock 12 Month Forecast
Average Price Target
$10.25
▲(234.97% Upside)
Technical Analysis
SELLAS Life Sciences Group
―
Galectin Therapeutics
―
Voyager Therapeutics
―
Diamedica Therapeutics
―
Instil Bio
―
Ownership Overview
8.93% Insiders
16.84% Mutual Funds
34.13% Other Institutional Investors
32.70% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---